332PRibociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2 –negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

ConclusionsSafety and efficacy outcomes in this post hoc analysis support the use of RIB + LET in pts with VM and BOM. Pts with BOM were less likely to have an objective tumor response but more likely to be progression free at 12 months, consistent with the more favorable prognosis of BOM compared with non-osseous metastases.Clinical trial identificationNCT02941926.Editorial acknowledgementMedical editorial assistance was provided by Joe Hodgson of Healthcare Consultancy Group, LLC, and funded by Novartis Pharmaceuticals Corporation.Legal entity responsible for the studyNovartis.FundingNovartis Pharmaceuticals.DisclosureM. De Laurentiis: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker ’s Honoraria, Advisory Board Honoraria: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker ’s Honoraria, Advisory Board Honoraria: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Celgene; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’ s Honoraria, Advisory Board Honoraria: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research